Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449150 · ClinicalTrials.gov registry record · Phase 3
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
A Phase 3 study, sponsored by AEterna Zentaris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 667
- Enrollment target
NCT00449150 is a Phase 3 study that was terminated before completion, run by AEterna Zentaris. The registered enrollment target is 667 participants.
The verdict
NCT00449150, a Phase 3 study, was terminated before completion, sponsored by AEterna Zentaris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 667 participants
- Enrollment target
Study Summary
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and among those aged 50 to 80, about 40% report moderate or severe urinary symptoms of prostatism. The aim of treatment is to improve patients' quality of life which primarily depends on the severity of the symptoms of BPH. Current treatments of BPH have a benefit / risk ratio which leaves room for improvement. For this study, study medication (Cetrorelix pamoate or placebo) is administered by injection in the buttocks (Intramuscular). All patients completing the double-blind portion (Week 0 to 52) are eligible to receive the active drug during the open-label part of the study (Week 52 to 90).
Interventions
- DRUG Placebo
- DRUG Cetrorelix 78 mg + 78 mg
- DRUG Cetrorelix 78 mg + 52 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00449150
The ClinicalTrials.gov registry entry for NCT00449150 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00449150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00449150 about?
NCT00449150 is a clinical study titled "Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)". Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and among those aged 50 to 80, about 40% report moderate or severe urinary sy...
What is the current status of trial NCT00449150?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 667 participants. The study started on 2007-03. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00449150?
The interventions under investigation include: Placebo (DRUG), Cetrorelix 78 mg + 78 mg (DRUG), Cetrorelix 78 mg + 52 mg (DRUG).
Who is sponsoring clinical trial NCT00449150?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.